Table 4.
Crude incidence rates (per 1,000 person years) and adjusted* hazard ratios (95% confidence intervals) for heart failure subtypes (HFrEF and HFpEF) adjudicated after 2005; according to categories of 6-year change in high sensitivity cardiac troponin T (hs-cTNT)
| Heart Failure Subtypes |
Absolute hs-cTNT change among all participants | Relative change among persons with measurable hs-cTNT values† |
|||||
|---|---|---|---|---|---|---|---|
| Incident Detectable (Baseline <5ng/L, Follow-up ≥5ng/L) |
Incident Elevated (Baseline <14ng/L, Follow-up ≥14ng/L) |
>50% Decrease |
Change ≤50% |
>50% Increase |
|||
| No (n=3599) |
Yes (n=1867) |
No (n=7306) |
Yes (n=286) |
(n=71) | (n=2038) | (n=996) | |
| HFrEF | n=88 | n=72 | n=256 | n=30 | n=5 | n=121 | n=77 |
| Incidence Rate |
3.72 (3.02–4.58) |
6.10 (4.84–7.69) |
5.45 (4.82–6.15) |
18.77 (13.1–26.8) |
11.61 (4.83–27.90) |
9.57 (8.01–11.44) |
13.15 (10.5– 16.4) |
| Demographic Model* |
1 (ref) | 1.51 (1.09–2.10) |
1 (ref) | 2.77 (1.88–4.10) |
1.44 (0.59–3.52) |
1 (ref) | 1.31 (0.99–1.75) |
| Full Model* | 1 (ref) | 1.54 (1.10–2.16) |
1 (ref) | 2.43 (1.62–3.65) |
0.85 (0.31–2.31) |
1 (ref) | 1.26 (0.94–1.69) |
| HFpEF | n=69 | n=67 | n=199 | n=17 | n=3 | n=76 | n=46 |
| Incidence Rate |
2.91 (2.30–3.69) |
5.68 (4.47–7.22) |
4.23 (3.68–4.86) |
10.63 (6.61–17.11) |
6.97 (2.25–21.60) |
6.01 (4.80–7.53) |
7.86 (5.89–10.49) |
| Demographic Model* |
1 (ref) | 1.87 (1.31–2.66) |
1 (ref) | 2.58 (1.55–4.31) |
1.18 (0.37–3.74) |
1 (ref) | 1.31 (0.91–1.90) |
| Full Model* | 1 (ref) | 1.72 (1.20–2.47) |
1 (ref) | 1.80 (1.06–3.05) |
1.06 (0.32–3.51) |
1 (ref) | 1.16 (0.80–1.69) |
Demographic Model- Adjusted for age, sex, race-center; Full Model- Adjusted for age, sex, race-center, body mass index (kg/m3), C-reactive protein (mg/L), smoking (current; former; never), drinking (current; former; never), systolic blood pressure (mmHg), current use of blood pressure-lowering medication (yes or no), diagnosed diabetes (yes or no), LDL-cholesterol (mg/dL), HDL-cholesterol (mg/dL), triglycerides (mg/dL), and current use of cholesterol-lowering medication (yes or no), estimated GFR (mL/min/1.73m2), and left ventricular hypertrophy (yes or no, by Cornell criteria).
Sample (N=3448) includes only those who have measurable hs-cTnT values (≥3 ng/L) at both visits. Relative change is calculated as a percent of baseline hs-cTNT. The full model for this relative change exposure is further adjusted for visit 2 hs-cTNT.